ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020
A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects.Nature communications · 2023Pooled it
- Clinical translation of polygenic scores for prostate cancer screening.Nature reviews. Urology · 2026Review
- Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.Nature cancer · 2026Article
- Primary healthcare-friendly prostate cancer prediction model using routine clinical parameters: a multicenter study.Frontiers in oncology · 2026Article
- Racial disparity in prostate cancer: an outlook in genetic and molecular landscape.Cancer metastasis reviews · 2024Review
- Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.Journal of the National Cancer Institute · 2024Article
- Clinical utility of polygenic risk scores: a critical 2023 appraisal.Journal of community genetics · 2023Article
- Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.Journal of the National Cancer Institute · 2023Article
- PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry.BMC cancer · 2022Article
- Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- SNPxE: SNP-environment interaction pattern identifier.BMC bioinformatics · 2021Article
- Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men.Prostate cancer and prostatic diseases · 2021Article
- Recent Insights on Genetic Testing in Primary Prostate Cancer.Molecular diagnosis & therapy · 2021Review
- A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.The Prostate · 2021Article
- Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.Prostate cancer and prostatic diseases · 2021Article
- Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management.Cancers · 2021Review
- Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.Nature communications · 2021Article
- Review
- Prostate cancer.Nature reviews. Disease primers · 2021Review
- African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.International journal of cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
64 authors.
Funding
Abstract
backgroundA polygenic hazard score (PHS), the weighted sum of 54 SNP genotypes, was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we assess the potential impact of PHS-informed screening.
methodsUnited Kingdom population incidence data (Cancer Research United Kingdom) and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer were combined to estimate age-specific clinically significant prostate cancer incidence (Gleason score ≥7, stage T3-T4, PSA ≥10, or nodal/distant metastases). Using HRs estimated from the ProtecT prostate cancer trial, age-specific incidence rates were calculated for various PHS risk percentiles. Risk-equivalent age, when someone with a given PHS percentile has prostate cancer risk equivalent to an average 50-year-old man (50-year-standard risk), was derived from PHS and incidence data. Positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was calculated using PHS-adjusted age groups.
resultsThe expected age at diagnosis of clinically significant prostate cancer differs by 19 years between the 1st and 99th PHS percentiles: men with PHS in the 1st and 99th percentiles reach the 50-year-standard risk level at ages 60 and 41, respectively. PPV of PSA was higher for men with higher PHS-adjusted age.
conclusionsPHS provides individualized estimates of risk-equivalent age for clinically significant prostate cancer. Screening initiation could be adjusted by a man's PHS. IMPACT: Personalized genetic risk assessments could inform prostate cancer screening decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.